NCT00303381 - Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis | Biotech Hunter

Enrollment

194

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

January 31, 2003

Study Completion Date

January 31, 2003

Conditions

Ulcerative Colitis

Interventions

DRUG

Interferon-beta-1a, 44 microgram

Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.

DRUG

Placebo

Matching Placebo will be administered subcutaneously, three times a week up to Week 8.

DRUG

Interferon-beta-1a, 66 microgram

Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.

Trial Locations (7)

Research Site, Munich

Research Site, Ness Ziona

Research Site, The Hague

Research Site, Singapore

Research Site, Solna

Research Site, Zug

Research Site, Feltham